ESAC Quality Indicators [25] | Group | Period | |
---|---|---|---|
Baseline (median 48 monthsb) | Post-intervention (median 19 monthsb) | ||
1. DID of antibiotics for systemic use | Intervention | 15.9 (15.8–16.0) | 13.8 (13.7–14.0) |
Control | 14.9 (14.8–15.0) | 13.5 (13.4–13.6) | |
2. DID of penicillins | Intervention | 9.1 (9.1–9.2) | 7.9 (7.8–8.0) |
Control | 8.0 (7.9–8.0) | 7.3 (7.3–7.4) | |
3. DID of cephalosporins | Intervention | 1.9 (1.9–1.9) | 1.5 (1.5–1.5) |
Control | 1.8 (1.8–1.8) | 1.5 (1.5–1.5) | |
4. DID of macrolides, lincosamides and streptogramins | Intervention | 1.6 (1.6–1.6) | 1.4 (1.4–1.4) |
Control | 1.7 (1.7–1.8) | 1.6 (1.5–1.6) | |
5. DID of quinolones | Intervention | 2.1 (2.1–2.1) | 1.9 (1.8–1.9) |
Control | 2.1 (2.1–2.1) | 1.9 (1.9–2.0) | |
6. PCT of beta-lactamase sensitive penicillinsa | Intervention | 0.6 (0.6–0.7) | 0.6 (0.5–0.6) |
Control | 0.4 (0.4–0.4) | 0.4 (0.3–0.4) | |
7. PCT of combinations of penicillins with beta-lactamase inhibitors a | Intervention | 42.1 (42.0–42.3) | 40.0 (39.8–40.3) |
Control | 39.0 (38.9–39.2) | 38.2 (38.0–38.4) | |
8. PCT of 3rd- and 4th-generation cephalosporins a | Intervention | 4.0 (3.9–4.0) | 2.8 (2.7–2.9) |
Control | 4.2 (4.8–4.3) | 3.3 (3.2–3.4) | |
9. PCT of quinolones | Intervention | 13.3 (13.2–13.4) | 13.4 (13.2–13.5) |
Control | 14.3 (14.2–14.4) | 14.3 (14.1–14.4) | |
10. Ratio of consumption of broad- to narrow-spectrum penicillins, cephalosporins and macrolides | Intervention | 68.9 (67.6–70.1) | 49.3 (47.5–51.0) |
Control | 59.9 (58.8–60.9) | 45.0 (43.6–46.5) |